Ratings by Goldman Sachs (Evie Koslosky)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/29/2026 | Adeptus Biotechnologies Corp. | ADPT | New Coverage | Buy (N/A) |
28.51 (25.51) |
-10.52% | Details | |
| 9/21/2026 | Tempus AI Inc | TEM | New Coverage | Neutral (N/A) |
80.36 (67.62) |
-15.85% | Details | |
| 6/5/2026 | Sotera Health | SHC | New Coverage | Buy (N/A) |
15.27 (18.10) |
18.53% | Details | |
| 6/5/2026 | GRAIL, Inc. | GRAL | New Coverage | Neutral (N/A) |
61.13 (132.55) |
116.83% | Details | |
| 6/5/2026 | Natera | NTRA | New Coverage | Neutral (N/A) |
211.85 (403.95) |
90.68% | Details | |
| 6/5/2026 | Guardant Health | GH | New Coverage | Buy (N/A) |
127.03 (169.08) |
33.1% | Details | |
| 4/13/2026 | Revvity Inc | RVTY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/13/2026 | Danaher | DHR | Maintain | Buy (N/A) |
|
Details | ||
| 4/1/2026 | Caris Life Sciences Inc | CAI | New Coverage | Buy (N/A) |
17.88 (32.00) |
78.97% | Details | |
| 2/27/2026 | Agilent | A | Maintain | Buy (N/A) |
|
Details | ||
| 2/13/2026 | Bruker | BRKR | Maintain | Sell (N/A) |
|
Details | ||
| 12/9/2025 | Bruker | BRKR | New Coverage | Sell (N/A) |
48.03 (57.59) |
19.9% | Details | |
| 12/9/2025 | Mettler-Toledo | MTD | New Coverage | Neutral (N/A) |
1414.86 (1670.29) |
18.05% | Details | |
| 12/9/2025 | Revvity Inc | RVTY | New Coverage | Neutral (N/A) |
100.79 (158.77) |
57.53% | Details | |
| 12/9/2025 | Danaher | DHR | New Coverage | Buy (N/A) |
226.25 (230.50) |
1.88% | Details | |
| 12/9/2025 | Agilent | A | New Coverage | Buy (N/A) |
145.49 (173.07) |
18.96% | Details | |
| 12/9/2025 | Thermo Fisher Scientific | TMO | New Coverage | Buy (N/A) |
572.77 (673.82) |
17.64% | Details |
